Who has invested in Antiva Biosciences?

MPM BioImpact Capital are named among the investors backing Antiva Biosciences.

Antiva Biosciences Funding: $100M Raised, Series E (2023)

Antiva Biosciences funding overview

Antiva Biosciences is based in South San Francisco, CA. Antiva Biosciences has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series E announced in April 2023. The round record for Antiva Biosciences runs through 2023; nothing later has been disclosed. Investors on record include MPM BioImpact Capital.

Antiva Biosciences at a glance

Total raised: $100M
Latest round: Series E
Latest round date: April 2023
Headquarters: South San Francisco, CA
Notable investors: MPM BioImpact Capital

Frequently asked about Antiva Biosciences funding

How much has Antiva Biosciences raised?: Antiva Biosciences has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Antiva Biosciences?: MPM BioImpact Capital are named among the investors backing Antiva Biosciences.
What was the latest Antiva Biosciences funding round?: The most recent disclosed round is a Series E, announced in April 2023.
Where is Antiva Biosciences based?: Antiva Biosciences is based in South San Francisco, CA.
When did Antiva Biosciences last raise?: The last disclosed Antiva Biosciences round closed in April 2023 at Series E.

Antiva Biosciences totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in South San Francisco below to benchmark round size and investor mix.

Antiva Biosciences Funding: $100M Raised, Series E (2023)

Antiva Biosciences funding overview

Antiva Biosciences at a glance

Frequently asked about Antiva Biosciences funding

Companies related to Antiva Biosciences (18)

Browse related funding lists (3)